بيتا
رادار التجارب AI

يتم الآن عرض التجارب السريرية الخاصة بـ أورام، أورام الثدي والمطابقة للموقع: فرنسا.

يمكنني مساعدتك على العثور على التجارب السريرية في مواقع محددة وتقديم رؤى طبية متقدمة حول الحالات الصحية والعلاجات.

مع الوضع المتقدم، يمكنك الوصول إلى أدوات الفرز المسبق القوية، وتصورات بيانية تفاعلية، وتنبيهات بريد إلكتروني مخصصة لتحديثات التجارب.

أداة البحث لدينا تدعم اللغة الإنجليزية فقط. للبحث والمناقشة بلغات أخرى، استخدم 'رادار التجارب AI' أعلاه أو حدد عوامل التصفية الخاصة بالحالة والموقع أدناه.
٨٦ نتائج
عرض أول ٥٠
 
حالة التجربة (افتراضي)
لم يبدأ القبول بعد, يقبل مشاركين, نشط (لا يقبل مشاركين جدد)
×
 
الحالة الطبية
أورام، أورام الثدي
×
 
الموقع
فرنسا
×
 
المرحلة
المرحلة الثانية
×
 
عنوان الدراسة
حالة التجربة
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (preEMBER) NCT07287098
لم يبدأ القبول بعد
دراسة عن إيزالونتاماب برينجيتيكان مقابل العلاج الكيميائي في المشاركين المصابين بسرطان الثدي الثلاثي السلبي المتقدم محليًا، أو المتكرر غير القابل للاستئصال، أو النقيلي غير المؤهل لأدوية مضادة لـ PD(L)1 (IZABRIGHT-Breast01) NCT06926868
يقبل مشاركين
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) NCT02734004
نشط (لا يقبل مشاركين جدد)النتائج المنشورة
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study NCT04641247
يقبل مشاركين
Study of the Impact of DPD Activity on the Efficacy of Capecitabine (DPDMAX) NCT04198727
نشط (لا يقبل مشاركين جدد)
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA) NCT05973864
يقبل مشاركين
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer (ELECTRA) NCT05386108
يقبل مشاركين
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) NCT02650401
نشط (لا يقبل مشاركين جدد)
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1) NCT05768139
يقبل مشاركين
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors NCT05888831
نشط (لا يقبل مشاركين جدد)
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX) NCT05986071
لم يبدأ القبول بعد
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies NCT04561362
نشط (لا يقبل مشاركين جدد)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types NCT04300556
يقبل مشاركين
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer (COMPASS-TNBC) NCT06508216
يقبل مشاركين
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer (ELEVATE) NCT05563220
يقبل مشاركين
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer NCT06840483
يقبل مشاركين
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors NCT05593094
نشط (لا يقبل مشاركين جدد)
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer (ALTER) NCT07151586
لم يبدأ القبول بعد
A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer (POP-ELA) NCT07159451
يقبل مشاركين
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer NCT06188559
نشط (لا يقبل مشاركين جدد)
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. NCT06206837
نشط (لا يقبل مشاركين جدد)
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) NCT06125522
نشط (لا يقبل مشاركين جدد)
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. (NeoB-Cap1) NCT06247995
يقبل مشاركين
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS BREAST) NCT04965766
يقبل مشاركين
Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk (LESS) NCT05297617
يقبل مشاركين
Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PRESAGE) NCT02890082
نشط (لا يقبل مشاركين جدد)
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT06726148
يقبل مشاركين
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer NCT07100106
يقبل مشاركين
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) NCT04551495
نشط (لا يقبل مشاركين جدد)
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064
يقبل مشاركين
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (PHERGain) NCT03161353
نشط (لا يقبل مشاركين جدد)
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07) NCT04538742
نشط (لا يقبل مشاركين جدد)
9-ING-41 in Patients with Advanced Cancers NCT03678883
نشط (لا يقبل مشاركين جدد)
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120) NCT04191499
نشط (لا يقبل مشاركين جدد)النتائج المنشورة
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer NCT01872260
نشط (لا يقبل مشاركين جدد)
Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic " Patient Reported Outcome ") on Breast-related Quality of Life (PRAVACUR-02) NCT04356209
يقبل مشاركين
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. (HEROES) NCT06450314
يقبل مشاركين
Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL (NEUROTAX) NCT05695313
يقبل مشاركين
دراسة لتقييم السلامة، والتحمل، ومستويات الدواء، والفعالية الأولية لمجموعات BMS-986507 لدى المشاركين البالغين المصابين بأورام صلبة متقدمة NCT06618287
يقبل مشاركين
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER) NCT04985266
يقبل مشاركين
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02) NCT03571633
نشط (لا يقبل مشاركين جدد)
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype (PONTIAC) NCT06486883
يقبل مشاركين
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer (H3RAKLES) NCT07193394
يقبل مشاركين
Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches) NCT03609047
نشط (لا يقبل مشاركين جدد)
GEN1047 for Solid Tumors - First in Human (FIH) Trial NCT05180474
نشط (لا يقبل مشاركين جدد)
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay) NCT03875573
نشط (لا يقبل مشاركين جدد)
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer NCT06827236
يقبل مشاركين
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer (PELICAN) NCT03515798
نشط (لا يقبل مشاركين جدد)
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors NCT05732831
يقبل مشاركين
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (ICARUSBREAST02) NCT06298084
يقبل مشاركين